SRRAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...

Stats
本日の出来高	0.00
平均出来高	651 457
時価総額	0.00
EPS	$0 ( 2022-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0.324 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-01	Vivo Opportunity, Llc	Sell	431 947	Common Stock
2022-07-01	Vivo Opportunity, Llc	Sell	75 749	Series A Warrants
2022-07-01	Orbimed Advisors Llc	Sell	226 704	Common Stock
2022-07-01	Orbimed Advisors Llc	Sell	170 437	Series A Warrants
2022-07-01	Ashiya Mona	Sell	226 704	Common Stock

INSIDER POWER
-97.16
Last 99 transactions
Buy: 4 604 902 \| Sell: 10 646 034

ボリューム相関

長: 0.15 (neutral)

短: -0.71 (moderate negative)

Signal:(77.923) Neutral

Sierra Oncology Inc 相関

10 最も正の相関
IIN	0.98
ECHO	0.98
MLVF	0.979
SIOX	0.972
EXFO	0.965
CDZI	0.963
GLRE	0.959
PROF	0.958
AMYT	0.958
BRAC	0.954

10 最も負の相関
SNPX	-0.986
PIII	-0.966
UTME	-0.965
BCAB	-0.963
MTP	-0.963
VORB	-0.961
SMFL	-0.961
RIVN	-0.955
PDBC	-0.95
OP	-0.949

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sierra Oncology Inc 相関 - 通貨/商品

-0.37
( neutral )

0.44
( neutral )

0.54
( weak )

-0.14
( neutral )

-0.32
( neutral )

0.40
( neutral )

Sierra Oncology Inc 財務諸表

Annual	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2020
収益:	$300 000
総利益:	$0.00 (0.00 %)
EPS:	$-7.70

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-30.30

Financial Reports:

No articles found.

Sierra Oncology Inc

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.